The US market is the one of consequence for MNTA investors insofar as this is where NVS/MNTA applied to approval to sell generic Copaxone. Below are quarterly Tysabri and Copaxone US sales for the past three years with the recent 1-year and 2-year growth rates.
Although Tysabri is still growing rapidly on a 1-year and 2-year basis, there was no growth to speak of in 4Q11 relative to 3Q11.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.